Initiation of Phase II trial of GDC-0449 in ovarian cancer triggers payment.



Genentech initiated a Phase II trial of GDC-0449, an orally administered small molecule Hedgehog pathway inhibitor, as a maintenance therapy for ovarian cancer patients in second or third complete remission. As a result, Curis will receive a $3 million cash payment from Genentech.


GDC-0449 was discovered by Genentech and was jointly validated by the two companies through a series of preclinical studies. Genentech and Roche collaborated on the clinical development and commercialization of GDC-0449. Curis is eligible to receive cash payments upon successful achievement of certain clinical development and regulatory approval milestones and royalties upon commercialization of GDC-0449.


GDC-0449 will be evaluated in approximately 100 patients with ovarian cancer in second or third complete remission. Patients will be randomized in a 1:1 ratio to receive either GDC-0449 or a placebo comparator and will be stratified based on whether their cancer is in a second or third complete remission. The primary endpoint of the trial is progression-free survival. Secondary outcome measures include overall survival, measurement of Hedgehog ligand expression in archival tissue, and number and attribution of adverse events.








This site uses Akismet to reduce spam. Learn how your comment data is processed.